Welcome and Introduction
Defining Castration Sensitivity in Metastatic and Nonmetastatic Prostate Cancer
Mechanism of Action and Comparisons of the Safety Profiles of Currently Available Androgen-Deprivation Therapies for Castration-Sensitive Prostate Cancer (CSPC)
Insights for Individualizing Treatment Options for Patients with CSPC
New Agents and Evolving Strategies in CSPC
Case Discussions Including Healthcare Professional-Patient Engagement Strategies
Key Takeaways and Audience Question and Answer Session
Date / Time
Michael S. Cookson, MD, MMHC, FACS
Professor and Chair
Department of Urology
The University of Oklahoma Health Sciences Center, College of Medicine
OU Health Stephenson Cancer Center, Prostate & Urologic Cancers Clinic
Oklahoma City, Oklahoma
Atish Choudhury, MD, PhD
Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
David F. Jarrard, MD
Professor and Vice Chair
Department of Urology
John P. Livesey Chair in Urologic Oncology
Associate Director for Translational Research
Carbone Cancer Center
University of Wisconsin School of Medicine and Public Health
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with prostate cancer.
This program is intended for oncologists and other healthcare professionals who care for patients with prostate cancer.
Upon completion of this activity, participants should be able to:
- Compare the mechanism of action, cardiovascular risk, and overall toxicity profiles associated with all approved systemic therapies for CSPC
- Apply cardioprotective strategies to reduce risk in patients with prostate cancer receiving ADT
- Plan optimal, individualized sequential therapeutic strategies for nonmetastatic or metastatic castration-sensitive prostate cancer, considering all available agents, clinical data, and expert recommendations
- Counsel patients on available therapies, taking into consideration patient preferences and comorbidities regarding differences in administration and safety profiles
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.